WALSH GEORGE J III
Known title: DirectorCIK: 0001207140
WALSH GEORGE J III's purchase track record
WALSH GEORGE J III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/4/2025 | CHE | $83K | +4.2% | +3.1% | +10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Transaction History
| CHE | ▼ Sell | Open Market | 500 | $219K | 5/29/2026 | View on chart |
| CHE | ▲ Buy | Grant | 386 | $170K | 5/18/2026 | View on chart |
| CHE | ▲ Buy | Open Market | 200 | $83K | 8/4/2025 | View on chart |
| CHE | ▲ Buy | Grant | 277 | $160K | 5/19/2025 | View on chart |
| CHE | ▼ Sell | Open Market | 400 | $239K | 9/26/2024 | View on chart |
| CHE | ▼ Sell | Open Market | 200 | $116K | 8/21/2024 | View on chart |
| CHE | ▲ Buy | Grant | 284 | $160K | 5/20/2024 | View on chart |
| CHE | ▲ Buy | Grant | 294 | $160K | 5/15/2023 | View on chart |
| CHE | ▲ Buy | Grant | 262 | $130K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Chemed to report Q3 2026 earnings on October 27
Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.
Chemed to report Q3 2026 earnings on October 27. Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.